Company Filing History:
2 out of 2 
2 out of 2 Years Active: 2021-2022
Title: Jiajia Mo: Innovator in Pharmaceutical Technology
Introduction
Jiajia Mo is a notable inventor based in Anhui, China. He has made significant contributions to the field of pharmaceutical technology, particularly in the treatment of skin inflammatory diseases. With a total of 2 patents, his work showcases innovative approaches to medicinal chemistry.
Latest Patents
One of Jiajia Mo's latest patents is a compound pharmaceutical composition for treating skin inflammatory diseases. This composition combines tofacitinib and crisaborole, resulting in a stronger therapeutic effect and lower dosage, demonstrating a significant synergistic therapeutic effect. This innovative pharmaceutical composition is designed to effectively treat various skin inflammatory conditions.
Another important patent involves a compound that inhibits phosphodiesterase 4 (PDE-4). This patent details a class of small molecule compounds, their preparation method, and their pharmaceutical applications. The pharmacodynamic tests confirm that this compound exhibits inhibitory activity against the PDE-4 enzyme, proving effective in inflammation treatment.
Career Highlights
Jiajia Mo has worked with prominent companies in the pharmaceutical industry, including Hefei Industrial Pharmaceutical Institute Co., Ltd and Hefei Amvite Pharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise in developing innovative pharmaceutical solutions.
Collaborations
Jiajia Mo has collaborated with various professionals in his field, including his coworker Zhaoxing Chu, who is also a talented woman in the pharmaceutical sector.
Conclusion
Jiajia Mo's contributions to pharmaceutical technology, particularly in treating skin inflammatory diseases, highlight his innovative spirit and dedication to improving healthcare solutions. His patents reflect a commitment to advancing medicinal chemistry and enhancing therapeutic efficacy.